Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100477 | 0.82 | L3MBTL1 (0.43) | FBP1ALDH1A1GAATSHRMAPT | |
| SCHEMBL7921437 | 0.79 | FBP1 (0.47) | FBP1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL28522622 | 0.73 | ALDH1A1 (0.61) | FBP1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL28605332 | 0.73 | ALDH1A1 (0.61) | FBP1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL9631776 | 0.73 | FBP1 (0.48) | FBP1KDM4ECYP2A6RAB9ACA1 | |
| SCHEMBL9631799 | 0.71 | EGFR (0.47) | FBP1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL11754100 | 0.71 | ALDH1A1 (0.50) | FBP1ALDH1A1LMNAGAACYP2A6 | |
| SCHEMBL506585 | 0.71 | RAB9A (0.58) | FBP1ALDH1A1KDM4ERAB9ATSHR | |
| SCHEMBL8039810 | 0.71 | CA12 (0.53) | FBP1ALDH1A1CA2CA12CA3 | |
| SCHEMBL8043742 | 0.71 | FBP1 (0.44) | FBP1ALDH1A1KDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5106723-A | Contrast enhancement layer compositions, alkylnitrones, and use | MICROSI, INC. (US) | 1992-04-21 | — | — | US | claimed |
| US-5002993-A | Contrast enhancement layer compositions, alkylnitrones, and use | MICROSI, INC. (US) | 1991-03-26 | — | — | US | claimed |
| US-6265400-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2001-07-24 | — | — | US | disclosed |
| EP-1091945-A1 | CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000481-A1 | CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-6004955-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0922039-A1 | CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998006707-A1 | CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0254221-B1 | CONTRAST ENHANCEMENT LAYER COMPOSITIONS, ALKYLNITRONES, AND USE | MicroSi, Inc. (a Delaware corporation) (US) | 1992-05-13 | — | — | EP | disclosed |
| US-5106723-A | Contrast enhancement layer compositions, alkylnitrones, and use | MICROSI, INC. (US) | 1992-04-21 | — | — | US | disclosed |
| US-5002993-A | Contrast enhancement layer compositions, alkylnitrones, and use | MICROSI, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0254221-A2 | Contrast enhancement layer compositions, alkylnitrones, and use | MicroSi, Inc. (a Delaware corporation) (US) | 1988-01-27 | — | — | EP | disclosed |